Cerus broke even on the bottom line, beating expectations, as INTERCEPT Fibrinogen Complex volumes grew roughly 80%. Positive topline Phase 3 RedeS data for the red blood cell system landed the same day, pushing a much larger market within regulatory reach.
Latest Activity
CERS Coverage
5 Stocks Wall Street and ARK’s Cathie Wood Love Are Trading Under $10 With Huge Upside Potential
These are five stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. While not suited for all investors, they are not penny stocks with…
Cathie Wood’s ARK Funds Are Loading Up on These 5 Red-Hot Stocks Trading Under $10
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
Cathie Wood’s ARK Funds Include 5 ‘Strong Buy’ Stocks Under $10 With Huge Upside Potential
These five stocks that Cathie Wood's ARK funds own millions of shares of are perfect for aggressive investors who look to get share count leverage on companies that have sizable upside potential.
5 Stocks Under $10 With Massive Upside Potential and ARK’s Cathie Wood Loves Two of Them
Here's a look at smaller cap companies that could very well offer patient investors some huge returns for the rest of 2023 and beyond.
Jim Cramer’s Game Plan for This Week and the Start of Earnings Season
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.